

**Performance in Initiating and Delivering (PID) Clinical Research**  
**UCLH Performance in Approving and Recruiting to Research**  
**July 2018**

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 1 (2018/19) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of July 2018.

For Further information on PID reporting, please visit the NIHR pages at:

<http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm>

Initiating Clinical Research – HRA Approval

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Date of First Participant Recruited	Benchmark Met	Reasons for delay correspond to:
122066	17/LO/0959	223644	LITTLE JOURNEY TRIAL	30/06/2017	01/07/2017	30/06/2017		06/07/2017		06/07/2017	14/07/2017	Yes	N/A
122067	14/LO/0187	143913	TAS-120	10/07/2017	04/07/2017			13/10/2017		06/11/2017	03/04/2018		Sponsor
122068	17/LO/0812	226255	Treatment with CD19/CD22 CAR redirected T cells for DLBCL-ALEXANDER	10/04/2017	06/07/2017			25/08/2017		05/09/2017	07/09/2017	Yes	N/A
122069	16/LO/2157	217001	Retrophin	29/09/2016	10/07/2017	13/07/2017		23/10/2017		20/12/2017			Neither
122070	17/LO/0506	220370	AMELIA	10/07/2017	12/07/2017	05/07/2017		20/09/2017		26/09/2017	25/01/2018		Neither
122071	17/NW/0168	218752	CA209-744	10/02/2017	17/07/2017	01/06/2017		09/08/2017		11/08/2017	12/10/2017		Neither
122072	17/LO/1019	223213	AFPc332T in Advanced HCC	09/02/2017	01/08/2017	15/09/2017		17/01/2018		05/02/2018			Sponsor
122073	17/EE/0291	203703	Phase III trial-pembrolizumab or brentuximab vedotin-Hodgkin Lymphoma	15/06/2017	03/08/2017			13/12/2017		14/12/2017	07/02/2018		Sponsor
122074	17/EM/0166	222665	AVAIL-T	05/05/2017	04/08/2017			07/08/2017		16/08/2017	27/11/2017		Neither
122075	17/ES/0051	223060	NuCana PRO-105	08/06/2017	07/08/2017			28/09/2017		28/09/2017	26/10/2017		Sponsor

122076	17/LO/0955	220437	MAKO medial unicompartmental knee arthroplasty	17/07/2017	08/08/2017	01/08/2017		15/08/2017	15/08/2017	24/11/2017		Sponsor
122077	17/LO/0797	220423	ABRE Study	28/02/2017	08/08/2017	01/08/2017		16/11/2017	30/11/2017	19/02/2018		Sponsor
122078	17/NE/0165	217768	MA30143	13/10/2016	09/08/2017			02/11/2017	06/11/2017	15/12/2017		Sponsor
122079	16/EE/0357	206501	Opicapone in clinical practice (OPTIPARK)	24/10/2016	09/08/2017	31/10/2016						Sponsor declined site confirmation
122080	17/LO/1055	228923	Elective rituximab in TTP	06/06/2017	10/08/2017	01/08/2017		31/08/2017	01/09/2017	13/10/2017	Yes	N/A
122081	17/LO/1060	187783	SUBSoNIC	10/08/2017	15/08/2017			14/11/2017	23/11/2017			Neither
122082	17/LO/1306	228268	REACH 3	27/07/2017	18/08/2017			06/02/2018	08/02/2018	21/05/2018		Sponsor
122083	17/LO/0618	223878	IMvigor 130	07/08/2017	18/08/2017			19/10/2017	09/11/2017	07/03/2018		Neither
122084	17/LO/0117	217367	ALLCAR19	09/08/2017	23/08/2017			25/09/2017	28/09/2017	01/10/2017	Yes	N/A
122085	17/EE/0384	218262	RCT of Apatinib in Patients with Advanced or Metastatic Gastric Cancer (GC)	07/02/2017	04/09/2017							Sponsor declined site confirmation
122086	17/LO/0977	200797	ICEMAN		06/09/2017			12/09/2017	12/09/2017	24/11/2017		Sponsor
122087	17/LO/0693	226490	Long-term safety of Everolimus in patients with TSC related seizures	27/06/2017	19/09/2017			25/09/2017	27/09/2017	10/10/2017	Yes	N/A

122088	16/LO/0994	204296	Study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783	25/08/2017	19/09/2017			19/02/2018	19/02/2018	08/03/2018		Sponsor	
122089	17/EE/0016	206408	A Randomised Control Trial of SEEG Electrode Placement methods	16/08/2017	25/09/2017			06/10/2017	06/10/2017	01/11/2017	Yes	N/A	
122090	16/EM/0324	204032	DEME 5472	20/07/2017	25/09/2017			24/11/2017	24/11/2017	17/01/2018		Sponsor	
122091	17/ES/0107	231506	Single arm study of Safety and Efficacy of Coversin in adult aHUS	20/07/2017	26/09/2017	14/09/2017		12/12/2017		31/01/2018		Sponsor	
122092	17/LO/0024	212247	Eli Lilly JPCJ	30/08/2016	03/10/2017			03/10/2017		03/10/2017	Yes	N/A	
122093	17/EE/0303	228718	Effect of MIN-102 in Male Patients with Adrenomyeloneuropathy	23/06/2017	03/10/2017			06/04/2018		06/04/2018	19/04/2018	Neither	
122094	17/LO/1043	226184	INCB24360:epacadostat in combination with pembrolizumab and azacitadine	14/02/2017	06/10/2017			25/10/2017		26/10/2017	21/11/2017	Yes	N/A
122095	17/LO/1656	229212	CO39722 IMspire 170	13/07/2017	09/10/2017	14/11/2017		19/12/2017		15/01/2018	22/05/2018	Neither	

122096	17/SC/0369	218189	NEPTUNES	24/05/2017	17/10/2017	06/10/2017		31/10/2017		30/11/2017	20/06/2018		Sponsor
122097	17/LO/1000	223047	Cryoablation (8 seconds) for the Management of Barrett's Oesophagus	10/10/2017	20/10/2017	10/10/2017		25/10/2017		10/11/2017	17/11/2017	Yes	N/A
122098	17/SW/0247	231651	NP39403-RO6870810 as monotherapy and in combination in advanced MM	21/09/2017	20/10/2017			22/01/2018		23/01/2018	19/03/2018		Sponsor
122099	17/NS/0065	219548	Physical Activity and Stoma Study	12/07/2017	31/10/2017			28/11/2017		28/11/2017	29/05/2018		Neither
122100	17/LO/1367	225049	MO29872: Atezolizumab compared with chemotherapy in NSCLC	25/05/2017	01/11/2017			02/11/2017		08/12/2017	06/03/2018		Neither
122101	17/NS/0077	218279	BLAST OSA study version 01	09/08/2017	01/11/2017			17/11/2017		07/12/2017			Sponsor
122102	17/EE/0376	232157	Anetumab ravtansine thorough ECG and drug interaction study with CYP3A4	31/07/2017	06/11/2017								Sponsor

122103	17/LO/1896	233209	A Phase 1 study of ADCT-502 in patients with advanced solid tumours	22/09/2017	06/11/2017	24/10/2017							Sponsor
122104	16/LO/1637	211258	First-in-human, trial of HuMax-AXL-ADC in patients with solid tumours	25/10/2017	07/11/2017		22/05/2018	25/05/2018		25/05/2018			Sponsor
122105	17/SC/0229	225742	OCTIMET OMO1	01/11/2017	07/11/2017			22/02/2018		23/02/2018	27/03/2018		Sponsor
122106	17/NE/0234	228388	MK3475-629	24/07/2017	08/11/2017			17/11/2017		20/11/2017	10/04/2018		Neither
122107	17/LO/1458	204582	ASD-Probiotic V.3	22/08/2017	09/11/2017			17/11/2017		17/11/2017	17/01/2018	Yes	N/A
122108	17/LO/1502	232726	ISIS-443139-CS2 - Open label extension study	12/09/2017	09/11/2017	09/11/2017		23/11/2017		23/11/2017	05/12/2017	Yes	N/A
122109	17/LO/0948	222446	FABULAS	02/11/2017	13/11/2017			25/12/2017		28/12/2017	22/02/2018		Sponsor
122110	17/EE/0370	233951	TNT009-01: SAFETY, TOLERABILITY AND ACTIVITY OF TNT009	23/08/2015	17/11/2017								Sponsor
122111	17/NS/0018	223787	FUTURE Study	13/10/2017	17/11/2017	11/08/2017		05/03/2018		06/03/2018			NHS Provider
122112	17/WS/0256	233393	BLU-667-1101	01/11/2017	30/11/2017			27/04/2018		27/04/2018			Sponsor
122113	17/LO/1861	210692	NEOlung	15/08/2016	06/12/2017			22/01/2018		25/01/2018	30/04/2018		Sponsor
122114	17/LO/1920	235022	Cardinal (BIVV009-03)	31/10/2017	08/12/2017								Sponsor

122115	17/LO/1921	236323	Cadenza (BIVV009-04)	31/10/2017	08/12/2017								Sponsor
122116	17/NW/0193	216411	IntAct	26/04/2017	12/12/2017			18/12/2017		08/02/2018			Neither
122117	17/LO/0038	182633	UKP3BEP Trial	08/03/2017	13/12/2017								Sponsor
122118	17/LO/1900	235038	INCB 01158-203	23/10/2017	20/12/2017	21/12/2017		20/02/2018		20/02/2018	01/03/2018		Sponsor
122119	17/SC/0605	234167	Starpharma CTX	05/01/2018	08/01/2018								Neither
122120	17/LO/1273	216265	CA209-648 (CheckMate 648)	22/05/2017	10/01/2018			18/01/2018		18/01/2018			Neither
122121	17/EE/0177	220722	BOSTON KCP-330-023	16/01/2018	29/03/2018								NHS Provider
122122	17/LO/1846	227211	Digital Interventions in Neuro-Rehabilitation (DINR) - Phase 1	18/12/2017	17/01/2018	18/12/2017		26/01/2018		26/01/2018	08/03/2018	Yes	N/A
122123	17/LO/1509	232288	MS-STAT2	01/09/2017	18/01/2018	16/01/2018		01/02/2018		02/02/2018	29/03/2018	Yes	N/A
122124	17/LO/1929	233885	Pembrolizumab+ epacadostat & EXTREME regimen 1st line Treat-R/M HNSCC	07/11/2017	18/01/2018			21/02/2018		27/02/2018			Neither
122125	17/LO/1808	231108	ICON9	04/07/2017	19/01/2018	18/12/2017							Sponsor
122126	17/YH/0289	231276	ACE-CL-110	02/01/2018	22/01/2018								Neither
122127	18/LO/0116	239646	Prexasertib in Recurrent Ovarian Cancer (JTJN)	02/01/2018	24/01/2018						17/04/2018		Sponsor
122128	16/EM/018	201126	TAMARIN	12/07/2017	26/01/2018			13/03/2018		13/03/2018			Neither

8	1											
122129	18/SC/0028	235714	CC-92480 Plus Dexamethasone in Relapsed and Refractory Multiple Myeloma	17/01/2018	29/01/2018							Neither
122130	18/LO/0226	231912	PF-06647020	21/09/2017	31/01/2018							Sponsor
122131	17/LO/1433	226791	WATS3D to detect oesophageal high grade dysplasia and adenocarcinoma	29/04/2017	01/02/2018			23/02/2018	23/02/2018	27/02/2018	Yes	N/A
122132	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	11/09/2017	02/02/2018			15/02/2018	15/02/2018			Neither
122133	14/NW/1238	160200	AZD6738	31/01/2018	07/02/2018			15/06/2018	15/06/2018			Sponsor
122134	18/LO/0047	235607	ARTISAN-SNM 105-0050	23/01/2018	08/02/2018			22/02/2018	23/02/2018	11/04/2018	Yes	N/A
122135	16/SC/0201	202977	Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients with Bilateral Idiopathic PD	07/09/2016	12/02/2018							Sponsor
122136	17/LO/1140	223446	K0-TIP-001	03/10/2017	14/02/2018						Yes	N/A
122137	17/EE/0368	213669	STRESS-L	01/09/2017	21/02/2018			19/03/2018	20/03/2018	19/04/2018	Yes	N/A



7													
122138	17/SS/0082	222441	SoSTART	10/09/2016	21/02/2018	05/10/2017	24/05/2018	31/05/2018					Neither
122139	17/WS/0147	184216	Precision Panc	06/12/2017	27/02/2018			01/03/2018		01/03/2018	28/06/2018		Neither
122140	17/LO/2032	235018	Patients with Metastatic Castration-Resistant Prostate Cancer	27/02/2018	02/03/2018								NHS Provider
122141	16/EE/0324	203951	PRO-DLI	12/09/2017	09/03/2018								Neither
122142	17/NI/0203	187583	Short pulse width DBS	08/01/2018	15/03/2018			23/03/2018		23/03/2018	02/05/2018	Yes	N/A
122143	17/LO/1972	231646	RCT: Direct Superior Approach vs Posterior Approach THA	02/02/2018	21/03/2018			03/04/2018		29/03/2018	07/07/2018		Neither
122144	17/EE/0518	236497	Interstim Amplitude study	06/10/2017	22/03/2018		09/04/2018	20/04/2018		20/04/2018	28/06/2018		Neither
122145	17/SC/0387	208972	mINivAN	20/09/2017	23/03/2018								Neither
122146	17/NE/0090	203556	SeluDex	01/02/2018	28/03/2018							Yes	N/A
125237	18/LO/0140	238756	SpectraCure P18 Study	09/11/2017	15/05/2018		19/06/2018					Yes	N/A
125238	17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dykinesia Study	13/04/2017	12/06/2018	17/01/2018	25/05/2018	22/06/2018		22/06/2018		Yes	N/A

125239	17/LO/1434	223047	Cryoablation (8 seconds) for the Management of Barrett's Oesophagus.	10/10/2017	20/10/2017	10/10/2017	25/10/2017	25/10/2017		10/11/2017	17/11/2017	Yes	N/A
125240	17/LO/0871	215297	MePFAC	03/08/2017	23/05/2018	05/04/2018	23/05/2018	24/05/2018		24/05/2018	29/06/2018	Yes	N/A
125241	18/NW/0172	242180	STEP 1 - Semaglutide Treatment Effect in People with obesity	15/12/2017	01/06/2018	17/05/2018	01/06/2018	15/06/2018		15/06/2018	26/06/2018	Yes	N/A
125242	18/LO/0370	241124	68Ga-THP-PSMA PET/CT imaging in primary and recurring prostate cancer	08/01/2018	24/05/2018	17/05/2018	13/06/2018	13/06/2018		15/06/2018	25/06/2018	Yes	N/A
125243	17/YH/0123	203556	SeluDex	01/02/2018	28/03/2018	12/12/2017							NHS Provider
125244	17/NE/0061	215780	CONVINCE - Protocol Version 2.1 29th November 2016	18/08/2017	05/04/2018	25/07/2017	15/05/2018	15/05/2018		15/05/2018			Neither
125245	15/NW/0376	115570	ReBeL Phase II (A HOVON 110FL/GLSG/NC RI study)	11/04/2017	05/04/2018								NHS Provider
125246	18/LO/0396	238968	NP40126 - A Phase 1B Study Evaluating RO7082859 in Lymphoma	15/03/2018	17/04/2018	16/05/2018							Neither

125247	17/NW/0512	221775	PETReA	06/10/2017	18/04/2018								NHS Provider
125248	18/EM/0119	244650	Chemotherapy+/- MK-3475 in TKI-resistant EGFR-mutated Tumors in NSCLC	13/02/2018	19/04/2018								Neither
125249	18/EM/0077	239257	FAST Study 1 (Fluidic Automated Screening for Trisomy Study 1)	04/10/2017	12/04/2018		19/04/2018	04/05/2018		04/05/2018	09/05/2018	Yes	N/A
125250	18/LO/0021	236581	EACH	27/03/2018	23/04/2018	26/03/2018						Yes	N/A
125251	16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	25/09/2017	18/04/2018	09/11/2016	03/05/2018	10/05/2018		11/05/2018	29/05/2018	Yes	N/A
125252	17/EM/0077	206480	LACI-2	24/08/2017	26/04/2018	24/07/2017	01/06/2018	12/06/2018				Yes	N/A
125253	18/LO/0448	241283	CALDOSE - 1	19/02/2018	01/05/2018	03/05/2018						Yes	N/A
125254	18/LO/0106	170254	HYPATIA study - Protocol Version 8.0	27/02/2018	08/05/2018	09/03/2018						Yes	N/A
125255	17/YH/0120	208838	DISC - Dupuytren's Interventions Surgery vs Collagenase	17/07/2017	16/05/2018	25/05/2017	05/06/2018	12/06/2018		12/06/2018		Yes	N/A
125256	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	24/11/2017	21/05/2018	05/01/2018	22/05/2018	30/05/2018		30/05/2018			Sponsor

125257	16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)	24/11/2017	21/05/2018						Yes	N/A
125258	18/LO/0144	239494	Intra-oral treatment of OLP with Rivelin?-CLO patches	04/12/2017	25/05/2018	17/05/2018					Yes	N/A
125259	17/LO/1678	211950	Lateral Flow Assay and Reader for Malaria Detection version 1.0	12/11/2017	29/05/2018			04/06/2018		04/06/2018	Yes	N/A
125260	17/WS/0081	225638	QUIDS 2	09/05/2018	29/05/2018	15/08/2017	13/06/2018	22/06/2018		22/06/2018		Sponsor
125261	17/LO/1898	233489	PKU Lophlex Evaluation	16/04/2018	04/06/2018						Yes	N/A
125262	18/LO/1156	239889	ANDROMEDA (54767414AMY3001)	12/06/2018	14/06/2018						Yes	N/A
125263	17/SC/0090	215068	c-TRAK TN	19/10/2017	20/06/2018						Yes	N/A
125264	16/LO/1355	168344	InPACT	31/10/2017	20/06/2018						Yes	N/A

Delivering Clinical Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
31237	15/SW/0220	182750	A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Axial Nonradiographic Spondyloarthritis	Number Agreed	3	3	Date Agreed	17/07/2017	1	02/07/2017	1	Withdrawn By Sponsor
31238	16/NW/0379	200426	LY2801653 and LY3009806 - Advanced or Metastatic Biliary Tract Cancer	Number Agreed	8	8	Date Agreed	01/05/2017	4	03/07/2017	4	Recruitment Finished
31239	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND,	Number Agreed	3	3	Not Available / Not Agreed			24/07/2017	1	Withdrawn By Sponsor

			PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE									
31240	16/EM/0165	203281	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (CANC 5545)	Number Agreed	2	2	Date Agreed	22/03/2018	2	28/07/2017	2	Recruitment Finished
31241	14/LO/2156	166004	A Phase 2 Proof of Concept (PoC), DoubleBlind, Randomised, Placebocontrolled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and	Number Agreed	75	75	Not Available / Not Agreed			31/07/2017	81	Recruitment Finished

			Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis.									
31242	16/EE/0243	207331	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	Number Agreed	5	5	Date Agreed	31/03/2017	1	05/09/2017	1	Withdrawn By Sponsor
31243	16/LO/1810	209789	UTX-TGR-304	Number Agreed	3	3	Date Agreed	30/05/2018	3	12/10/2017	0	Recruitment Finished
31244	10/H1102/44	0	MCRN146 (AC-056C501)	Not Available / Not Agreed			Not Available / Not Agreed			19/10/2017	2	Recruitment Finished
31245	16/LO/1436	205613	Potential Predictors of Disease Progression in aHUS Patients	Number Agreed	10	10	Date Agreed	30/06/2018	6	31/10/2017	6	Recruitment Finished
31246	15/LO/1936	183134	CANC - 4615	Number Agreed	3	3	Date Agreed	31/05/2017	0	13/11/2017	2	Withdrawn By Sponsor

31247	17/EM/0089	222705	BREAKOUT	Number Agreed	10	10	Date Agreed	28/02/2018	1	15/11/2017	1	Withdrawn By Sponsor
31248	16/SS/0134	199690	STRO 4724	Number Agreed	1	1	Not Available / Not Agreed			17/11/2017	1	Withdrawn By Sponsor
31249	16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	Number Agreed	1	1	Not Available / Not Agreed			20/11/2017	0	Recruitment Finished
31250	15/LO/1950	184545	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence II)	Number Agreed	10	10	Date Agreed	01/11/2017	11	30/11/2017	11	Recruitment Finished
31251	17/SC/0033	218114	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in	Number Agreed	2	2	Not Available / Not Agreed			01/01/2018	3	Recruitment Finished



			combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory mu									
31252	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	10	10	Not Available / Not Agreed			12/01/2018	0	Withdrawn By Sponsor
31253	17/LO/0640	204303	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders associated with	Number Agreed	3	3	Date Agreed	31/12/2017	2	31/01/2018	2	Recruitment Finished

			Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)									
31254	16/LO/0574	150998	Phase I/II, First in Human, Dose Escalation Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with Relapsed/Refractory B Cell Malignancies and Expansion Cohorts in Patients with Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma	Number Agreed	6	6	Not Available / Not Agreed			31/01/2018	3	Recruitment Finished
31255	16/NE/0142	202233	A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with	Number Agreed	3	3	Not Available / Not Agreed			01/02/2018	6	Recruitment Finished

			Previously Untreated Epithelial Ovarian Cancer									
31256	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Number Agreed	4	4	Not Available / Not Agreed			05/02/2018	3	Recruitment Finished
31257	17/NW/0228	222219	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma	Number Agreed	2	2	Date Agreed	30/04/2018	5	13/02/2018	5	Recruitment Finished

31258	16/WM/0512	218042	A Phase 1, Open-label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or witho	Number Agreed	9	9	Not Available / Not Agreed			15/03/2018	1	Recruitment Finished
31259	15/LO/0685	148762	A comparison of Glycosade? and Uncooked Cornstarch (UCCS) for the treatment of hepatic glycogen storage diseases (GSD)	Number Agreed	2	2	Date Agreed	01/04/2016	3	31/03/2018	3	Recruitment Finished
31260	17/NE/0201	218005	A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)	Number Agreed	8	8	Not Available / Not Agreed			31/01/2018	10	Recruitment Finished

31345	17/LO/0169	214075	SPI2	Number Agreed	15	15	Date Agreed	30/09/2017	6	11/05/2018	17	Recruitment Finished
31346	16/EM/0252	202691	LemQoL	Number Agreed	6	6	Not Available / Not Agreed			14/05/2018	6	Recruitment Finished
31347	15/SC/0659	189114	DEME 4996	Number Agreed	2	2	Date Agreed	28/04/2017	0	08/06/2018	11	Withdrawn By Sponsor
31348	16/EE/0296	210289	A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome	Number Agreed	4	4	Date Agreed	31/10/2016	0	26/04/2018	4	Recruitment Finished
31349	17/NE/0115	218417	MA39189	Number Agreed	3	3	Date Agreed	30/04/2018	0	01/03/2018	1	Recruitment Finished
31350	16/SC/0035	194232	A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S	Number Agreed	18	18	Not Available / Not Agreed			31/03/2018	18	Recruitment Finished
31351	16/NE/0342	213304	ADCT-402-101	Number Agreed	17	17	Date Agreed	28/02/2018	17	Apr-18	17	Recruitment Finished
31352	14/NW/1092	142160	NCRN - 2674: Autologous EBV-specific T-cells for the treatment of ENKTCL	Number Agreed	2	2	Date Agreed	30/12/2015	0	01/11/2017	5	Withdrawn By Host
31353	17/EM/0208	225066	COSIMO: Cancer associated thrombosis-patient reported	Not Available / Not Agreed			Not Available / Not Agreed			15/05/2018	18	Recruitment Finished

			outcomes									
31354	16/WM/0433	215494	TRAIT	Not Available / Not Agreed			Date Agreed	29/01/2016	0	30/04/2018	32	Recruitment Finished
31355	12/SC/0584	109643	CCRN 1093 (aHUS)	Number Agreed	30	30	Date Agreed	30/06/2017	26	10/01/2018	32	Withdrawn By Sponsor
31356	16/LO/1782	213379	Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer	Number Agreed	3	3	Date Agreed	30/01/2017	0	01/02/2018	5	Withdrawn By Sponsor
31357	17/EE/0128	222308	N/A	Not Available / Not Agreed			Not Available / Not Agreed			21/05/2018	2	Recruitment Finished
31358	15/LO/2098	182147	CRIT 3822	Number Agreed	14	14	Date Agreed	28/12/2015	0	11/12/2017	15	Withdrawn By Sponsor
31359	15/SC/0676	186964	CANC - 3899 Olaratumab plus doxorubicin vs. placebo plus doxorubicin advanced or metastatic STS	Not Available / Not Agreed			Date Agreed	30/06/2017	1	27/05/2018	1	Recruitment Finished
31360	17/LO/1043	226184	ECHO 206: epacadostat in combination with pembrolizumab	Not Available / Not Agreed			Not Available / Not Agreed			14/05/2018	52	Withdrawn By Sponsor

			and azacitadine									
31361	16/NW/0086	198831	CANC - 4775	Number Agreed	2	2	Date Agreed	29/04/2016	0	08/05/2018	0	Withdrawn By Sponsor
31362	16/EE/0463	214371	CompLEEment-1	Number Agreed	10	10	Date Agreed	30/12/2019	0	16/10/2017	10	Recruitment Finished
31363	17/LO/0436	214612	Development of an MCM5 ELISA test for oesophageal cancer	Not Available / Not Agreed			Date Agreed	30/11/2017	0	14/05/2018	0	Recruitment Finished
31364	17/LO/0627	218496	Study of VAL-1221 in Patients with Pompe Disease (VAL-1221-201-16)	Number Agreed	4	4	Date Agreed	31/08/2017	0	14/05/2018	4	Recruitment Finished
31365	15/LO/1906	192701	GAST 5150	Not Available / Not Agreed			Not Available / Not Agreed			30/04/2018	3	Recruitment Finished
31366	16/NE/0353	211988	ARASENS	Number Agreed	4	4	Date Agreed	28/04/2017	0	22/03/2018	7	Recruitment Finished
31367	15/SC/0009	170938	CANC - 4476	Not Available / Not Agreed			Date Agreed	30/05/2016	0	20/06/2018	12	Recruitment Finished
31368	14/WS/1146	166537	STRO 3595 NAVIGATE ESUS	Number Agreed	10	10	Date Agreed	31/07/2015	0	20/09/2017	25	Withdrawn By Sponsor
31369	15/LO/1979	181054	NEUR 4538	Not Available / Not Agreed			Date Agreed	30/12/2016	13	31/03/2018	38	Recruitment Finished
31370	17/LO/0693	226490	Long-term safety of Everolimus in patients with TSC related seizures	Number Agreed	2	2	Date Agreed	27/09/2017	0	23/10/2017	2	Recruitment Finished

31371	17/LO/1502	232726	ISIS-443139-CS2 - Open label extension study	Number Agreed	6	6	Date Agreed	30/05/20 18	9	12/03/20 18	7	Recruitment Finished
31372	13/EE/0326	137999	SRN066 Revacept in Carotid Artery Stenosis	Not Available / Not Agreed			Date Agreed	30/06/20 15	12	14/05/20 18	8	Recruitment Finished